申请人:SMITHKLINE BEECHAM CORPORATION
公开号:EP0425212A2
公开(公告)日:1991-05-02
This invention relates to compounds of the formula:
wherein:
A′MIN′ is absent, Asn, Gln, Ala or Abu;
A is absent or a D- or L- amino acid chosen from Arg, HArg, (Me₂)Arg, (Et₂)Arg, Abu, Ala, Gly, His, Lys, or an α-R′MIN′ substituted derivative thereof, Dtc, Tpr or Pro;
B is a D- or L- amino acid chosen from Arg, HArg, NArg, (Me₂)Arg, (Et₂)Arg, Lys or an α-R′MIN′ substituted derivative thereof;
Q is absent or a D or L amino acid chosen from Tyr, (Alk)Tyr, Phe, (4′MIN′W)Phe, HPhe, Phg, Pro, Trp, His, Ser, (Alk)Ser, Thr, (Alk)Thr, (Alk)Cys, (Alk)Pen, Ala, Val, Nva, Met, Leu, Ile, Nle or Nal, or an α-R′MIN′ substituted derivative thereof;
M is Gly or D or L Glu, Phe, Pro, Lys, Ser or, provided n is 1, B-Gly-Glu-Q;
or a pharmaceutically acceptable salt thereof;
which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, a method for inhibiting platelet aggregation and clot formation in a mammal, and a method for inhibiting reocclusion of a blood vessel following fibrinolytic therapy.
本发明涉及式中的化合物:
其中
A′MIN′为缺失、Asn、Gln、Ala或Abu;
A 是不存在的或选自 Arg、HArg、(Me₂)Arg、(Et₂)Arg、Abu、Ala、Gly、His、Lys 或其 α-R′MIN′ 取代衍生物、Dtc、Tpr 或 Pro 的 D-或 L-氨基酸;
B 是 D-或 L-氨基酸,选自 Arg、HArg、NArg、(Me₂)Arg、(Et₂)Arg、Lys 或其 α-R′MIN′ 取代的衍生物;
Q 是不存在的或选自 Tyr、(Alk)Tyr、Phe、(4′MIN′W)Phe、HPhe、Phg、Pro、Trp、His、Ser、(Alk)Ser、Thr、(Alk)Thr、(Alk)Cys、(Alk)Pen、Ala、Val、Nva、Met、Leu、Ile、Nle 或 Nal 的 D 或 L 氨基酸或其 α-R′MIN′ 取代的衍生物;
M 是 Gly 或 D 或 L Glu、Phe、Pro、Lys、Ser 或(如果 n 为 1)B-Gly-Glu-Q;
或其药学上可接受的盐;
有效抑制血小板聚集的药物组合物、实现这种活性的药物组合物、抑制哺乳动物体内血小板聚集和凝块形成的方法,以及抑制纤维蛋白溶解疗法后血管再闭塞的方法。